TNFRSF4 and Alzheimer disease: Fezakinumab (anti-IL-22), GBR830 (anti-OX40), itepekimab (anti-IL-33) mepolizumab (anti-IL-5), omalizumab (anti-IgE) ustekinumab (anti-IL-12/23p40), risankizumab (anti-IL-23p19), rocatinlimab (anti-OX40), secukinumab (anti-IL-17A), and tezepelumab (thymic stromal lymphopoietin) showed poor or uncertain efficacy in AD (130–147).